

1 **Appendix**

2 **Genotype-specific differences in infertile men due to loss-of-function variants in *M1AP***  
3 **or *ZZS* genes**

4 Nadja Rotte<sup>1</sup>, Jessica E.M. Dunleavy<sup>2</sup>, Michelle D. Runkel<sup>1</sup>, Daniela Fietz<sup>3</sup>, Adrian Pilatz<sup>4</sup>,  
5 Johanna Kuss<sup>1</sup>, Ann-Kristin Dicke<sup>1</sup>, Sofia B. Winge<sup>7</sup>, Sara Di Persio<sup>5</sup>, Christian Ruckert<sup>6</sup>,  
6 Verena Nordhoff<sup>5</sup>, Hans-Christian Schuppe<sup>4</sup>, Kristian Almstrup<sup>7,8</sup>, Sabine Kliesch<sup>5</sup>, Nina  
7 Neuhaus<sup>5</sup>, Birgit Stallmeyer<sup>1</sup>, Moira K. O'Bryan<sup>2</sup>, Frank Tüttelmann<sup>1</sup>, Corinna Friedrich<sup>1</sup>

8

9	<b>Table of Content</b>
10	<b>Appendix Methods</b>
11	<b>Appendix Tables</b>
12	Appendix Table S1. Clinical parameters of infertile men analysed in this study
13	Appendix Table S2. Published cases of male infertility due to LoF variants in <i>M1AP</i> , <i>SHOC1</i>
14	or <i>TEX11</i> .
15	Appendix Table S3. Antibody information.
16	Appendix Table S4. Primer information.
17	<b>Appendix Figures</b>
18	Appendix Figure S1. <i>M1AP</i> splice site variant identified in M3609.
19	Appendix Figure S2. <i>SHOC1</i> splice site variant identified in M3260.
20	Appendix Figure S3. <i>SPO16</i> loss-of-function variant identified in M3863.
21	Appendix Figure S4. Overview of clinical data of men with loss-of-function variants in <i>M1AP</i> ,
22	<i>SHOC1</i> , <i>TEX11</i> or <i>SPO16</i> .
23	Appendix Figure S5. PAS (N=7) or H&E (N=3) staining of men with LoF variants in <i>M1AP</i> .
24	Appendix Figure S6. PAS (N=7) or H&E (N=3) staining of men with LoF variants in <i>SHOC1</i> ,
25	<i>TEX11</i> or <i>SPO16</i> .
26	Appendix Figure S7. CREM staining in men with loss-of-function variants in <i>M1AP</i> , <i>SHOC1</i> ,
27	<i>TEX11</i> or <i>SPO16</i> .
28	Appendix Figure S8. $\gamma$ H2AX localisation showed meiosis prophase I progression in men with
29	loss-of-function variants in <i>M1AP</i> .
30	Appendix Figure S9. $\gamma$ H2AX localisation showed impaired meiosis prophase I progression in
31	men with loss-of-function variants in <i>SHOC1</i> , <i>TEX11</i> or <i>SPO16</i> .
32	Appendix Figure S10. Metaphase I cells were determined by H3S10p localisation in men with
33	loss-of-function variants in <i>M1AP</i> , <i>SHOC1</i> , <i>TEX11</i> or <i>SPO16</i> .
34	Appendix Figure S11. Quantification of apoptosis in men with loss-of-function variants in
35	<i>M1AP</i> , <i>SHOC1</i> , <i>TEX11</i> or <i>SPO16</i> via TUNEL.
36	Appendix Figure S12. Human spermatocyte spreads showed the absence of crossover in ZZS
37	cases.
38	Appendix Figure S13. Human spermatocyte spreads showed meiotic delay in ZZS cases.
39	Appendix Figure S14. Euploidy analysis of M2746, his child, and the child's mother.
40	Appendix Figure S15. Staining of testicular tissue from a representative human control.
41	Appendix Figure S16. Digital droplet PCR confirmed the deletion of exons 1-11 in M2820.
42	Appendix Figure S17. Digital droplet PCR confirms the deletion of exons 10-11 in M3152.
43	<b>Appendix References</b>

## 44 **Appendix Methods**

### 45 **Exome and genome sequencing**

46 Genomic DNA was extracted from peripheral blood leucocytes by standard methods. For  
47 exome sequencing, samples were prepared and enrichment was performed according to the  
48 protocols of either Agilent's SureSelectQXT target enrichment for Illumina multiplexed  
49 sequencing featuring transposase-based library prep technology or Twist Bioscience's twist  
50 human core exome. For library capturing, Agilent's SureSelect human all exon kits V4, V5, and  
51 V6 or Twist Bioscience's human core exome plus RefSeq spike-in and exome 2.0 plus  
52 comprehensive spike-in were used. Sample multiplexing was achieved by tagging the libraries  
53 with appropriate index primer pairs. Quality and quantity was determined using the  
54 ThermoFisher Qubit, the Agilent TapeStation 2200, and the Tecan Infinite 200Pro microplate  
55 reader. Finally, sequencing itself was performed on the Illumina HiSeq 4000, the Illumina  
56 HiSeqX, the Illumina NextSeq 500, the Illumina NextSeq 550, or the NovaSeq 6000 system,  
57 using the HiSeq 3000/4000 SBS (300 cycles), the HiSeq X Ten Reagent (300 cycles), the  
58 NextSeq 500 V2 high-output (300 cycles), or the NovaSeq 6000 S1 and S2 reagent kits v1.5  
59 (200 cycles), respectively. Exome sequencing and analysis of patient GEMINI-377 has been  
60 described previously (Nagirnaja et al., 2022).

61 Genome sequencing libraries were prepared with Illumina's DNA PCR-Free library kit. Index  
62 tagging for multiplexed sequencing was accomplished by employing suitable pairs of index  
63 primers. DNA and library quantity and quality were assessed using the ThermoFisher Qubit  
64 and the Tecan Infinite 200 Pro Microplate Reader, respectively. Sequencing was performed  
65 on the NovaSeq 6000 System, utilising NovaSeq 6000 S1, S2, and S4 Reagent kits v1.5 (300  
66 cycles), respectively.

### 67 **Variant calling**

68 Adapter sequences and primers were trimmed using Cutadapt v1.15 (Martin, 2011) and reads  
69 were aligned against Genome Reference Consortium human build 37 (GRCh37.p13) with  
70 BWA Mem v0.7.17 (Li and Durbin, 2010). Recalibration of base quality and variant calling was

71 performed with the GATK toolkit v3.8 (McKenna *et al.*, 2010) or with the with Illumina Dragen  
72 Bio-IT platform v4.2, both with haplotype caller according to the best practice  
73 recommendations. Duplicate reads or reads mapping to multiple locations in the exome were  
74 excluded. Identified variants were annotated using the Ensembl variant effect predictor  
75 (McLaren *et al.*, 2016).

### 76 **Cohort screening for high impact variants**

77 The MERGE sequencing data was screened for loss-of-function (LoF) (start-loss, stop-gain  
78 and frameshift) and splice site variants ( $\pm 20$  nucleotides) in *M1AP*, *SHOC1* [*C9orf84*], *TEX11*,  
79 and *C1orf146* [*SPO16*]. For consistency in the manuscript, we used the HGNC  
80 (<https://www.genenames.org/>) approved gene symbols for *M1AP*, *SHOC1*, and *TEX11*,  
81 whereas we refer to *C1orf146* using its alias symbol, *SPO16*. We considered only variants  
82 corresponding to the respective mode of inheritance for each gene (*M1AP/SHOC1/SPO16* =  
83 autosomal recessive (AR), *TEX11* = X-linked recessive (XR)). Resulting variants were filtered  
84 for the general population frequency (gnomAD database v2.1.1; (Karczewski *et al.*, 2020;  
85 minor allele frequency [MAF]  $\leq 0.01$  (AR) or  $\leq 0.001$  (XR)) and an occurrence  $\leq 30$  times in our  
86 in-house database containing 4,377 datasets from individuals with other genetic diseases. As  
87 reference, the longest transcript per gene with the highest testicular expression (according to  
88 GTEx; (Yu *et al.*, 2011) was selected (*M1AP*: NM\_001321739.2, *SHOC1*: NM\_173521.5,  
89 *TEX11*: NM\_1003811.2, and *SPO16*: NM\_001012425.2). Nonsense-mediated decay  
90 prediction was performed by (<https://www.mutationtaster.org/>).

91 The sequencing data was analysed for second hits present in a list of 18 azoospermia genes  
92 with at least moderate clinical validity (Wyrwoll *et al.*, 2023) and 363 candidate genes with  
93 strong expression in human male germ cells and an associated Gene Ontology classification  
94 of *male infertility* in the Mouse Genome Informatics Database.

### 95 **Variant validation and segregation analyses**

96 Identified SNVs were confirmed by Sanger sequencing. Similarly, DNA from family members  
97 was analysed for co-segregation attempts and to show if variants occur biallelic. Briefly, the

98 region of interest was amplified using respective primers listed in Appendix Table S3.  
99 Purification of PCR products and sequencing was performed according to standard protocols.

100 For validation of deletions, droplet digital PCR (ddPCR) was used as described previously  
101 (Dicke et al., 2023). In brief, ddPCR was carried out using the QX200 droplet digital PCR  
102 system (Bio-Rad, #1864001), the ddPCR supermix for probes (no dUTP) (Bio-Rad,  
103 #1863024), respective primers/probes (final concentrations: 200 nM, Appendix Table S3), and  
104 100 ng template DNA in a final volume of 20  $\mu$ l. For restriction digestion, HaeIII was used.  
105 Droplets were generated using the QX200™ droplet generator (Bio-Rad, #1864002) followed  
106 by a two-step cycling protocol, set at 95°C for 10 min, with 40 cycles of 94°C for 30 s and 58°C  
107 for 1 min, with a final extension of 98°C for 10 min and a 4°C hold. The final analysis was  
108 performed with 6-FAM- and HEX-channels using the QX200 droplet reader (Bio-Rad,  
109 #1864003). Droplet digital PCR validated the identified deletions in M2820 and M3152  
110 (Appendix Figure S16/S17)

### 111 **Ploidy analysis from genome sequencing data of M2746's offspring**

112 Ploidy for autosomes and gonosomes was estimated using Illumina DragenBio-IT Platform  
113 v4.2. Read counts were normalised by dividing the median read count of each chromosome  
114 by the median read count of all autosomes. Data is depicted as  $\log^2$ .

### 115 **Minigene splicing assay**

116 The functional impact of the splice site variants *M1AP* c.1073\_1074+10del and *SHOC1*  
117 c.1939+2T>C was determined by *in vitro* splicing assays based on a case-specific minigene  
118 construct. Therefore, the affected region of interest was cloned with adjacent intronic  
119 sequences encompassing the variant of interest in a eukaryotic expression vector  
120 (pDESTsplice) suitable to analyse splicing events. The artificial minigene construct used in this  
121 study consists of two known exons of rat *Insulin 2*, exon 3 and 4, separated by intronic  
122 sequences. Using a two-step cloning technique results in the insertion of the region of interest  
123 into those intronic sequences separating the known exons. The region of interest was amplified  
124 from genomic DNA of the respective individual or a human male control sample with standard

125 PCR technique. Primers are listed in Appendix Table S4. 0.5 U/ $\mu$ L Phusion<sup>TM</sup> high-fidelity DNA  
126 polymerase (Thermo Scientific, # F530) was used for amplification according to the  
127 manufacturer's instructions. Cloning into a pENTR/D-TOPO<sup>®</sup> vector (Thermo Scientific,  
128 #K240020) was followed by LR recombinase reaction and gateway cloning using the  
129 Gateway<sup>TM</sup> LR clonase<sup>TM</sup> enzyme mix (Thermo Scientific, #11791020) and an ultimate  
130 pDESTsplice vector (a gift from Stefan Stamm (addgene plasmid #32484, Kishore, Khanna  
131 and Stamm, 2008). Subsequently, HEK293T cells were transiently transfected with 2  $\mu$ g of  
132 wildtype or case-specific minigene DNA constructs using the K2 transfection reagent according  
133 to the manufacturer's instructions. After 24 hours of transfection, total RNA was extracted  
134 using the RNeasy plus mini kit (Qiagen, #74134) and transcribed into cDNA using the  
135 ProtoScript<sup>®</sup> II first strand cDNA synthesis kit (New England Biolabs, #E6560). Amplification  
136 was conducted with primers annealing to rat insulin exon 3 and exon 4, respectively. Finally,  
137 RT-PCR products were separated on a 2% agarose gel, visualised with the TapeStation D1000  
138 system (Agilent, #5067-5582), cut out and extracted, and confirmed by Sanger sequencing  
139 following standard protocols.

#### 140 **Protein structure predictions**

141 Presented protein structures (M1AP, SPO16) were predicted using AlphaFold2 from EMBL-  
142 EBI (Jumper et al., 2021; Varadi et al., 2024). Images of protein structures were adapted in  
143 colour or variant consequences and exported from the EBI server.

144

145 **Appendix Tables**146 **Appendix Table S1. Clinical parameters of infertile men analysed in this study.**

Case	FSH [U/L]	LH [U/L]	Testosterone [nmol/L]	Testicular volume [mL] – right/left	Reference
<b>M1AP</b>					
M330	9	5.3	14.6	17/23	Wyrwoll et al., 2020
M864	4.7	1.5	9.6	19/26	Wyrwoll et al., 2020
M1792	7.8	5.1	10.1	15/15	Nagirnaja et al., 2022; Wyrwoll et al., 2020
M2062	3.5	3.6	18.6	26/23	Wyrwoll et al., 2023, 2020
M2525	15.4	7.7	10.2	22/29	
M2746	3.5	2.4	18.5	18/16	
M2747	9.7	3.6	19.9	8/8	
M3402	7.2	5.2	10.7	15/14	
M3511	3	2.1	8.9	22/13	
M3609	3.8	3.7	17.1	10/10	
<b>SHOC1</b>					
M2012	5.9	4.6	17.1	23/19	Krausz et al., 2020
G-377	4.9	7.4	29.6	NA	Nagirnaja et al., 2022
M2046	15.9	10.1	6.3	10/10	Krausz et al., 2020
M3260	4.8	5.2	11.9	18/13	
<b>TEX11</b>					
M205	6	2.5	15.1	25/5*	Yatsenko et al., 2015
M246	3.3	4.1	10.9	26/22	
M281	2.9	2.2	12.8	20/16	Yatsenko et al., 2015
M1390	11.6	5.9	13.1	12/10	Wyrwoll et al., 2023
M2739	7.3	3.1	15.8	28/28	
M2820	15.9	5.2	10.4	14/5*	
M2942	5.5	2	14	15/17	
M3152	5.3	3.6	22	11/10	
M3409	7.1	5.3	8.9	10/10	

**SPO16**

---

M3609	5.7	4.1	14.2	11/13
-------	-----	-----	------	-------

---

abbreviations: FSH = follicle-stimulating hormone, LH = luteinising hormone, NA = not available. All parameters were obtained at the first visit. \*diagnosed and treated varicocele at the age of 18, led to testis atrophy (left side), †maldescended testis (left side).

reference values: FSH = 1-7 IU/L, LH = 2-10 IU/L, T = >12 nmol/L, TV = >12 mL per testis (right/left).

147



148 **Appendix Table S2. Published cases of male infertility due to LoF variants in *M1AP*, *SHOC1* or *TEX11*.**

Case #	Case ID	LoF variant	Genotype	Phenotype	Transcript	Reference	
<b>M1AP</b>							
1	M330			azoo (MeiA – SPC), TESE negative	NM_138804.4	Wyrwoll et al., 2020	
2	M864			azoo (MeiA – SPC), TESE negative	NM_138804.4	Wyrwoll et al., 2020	
3	M1792			azoo (MeiA – SPC), TESE negative	NM_138804.4	Nagirnaja et al., 2022; Wyrwoll et al., 2020	
4	M2062	c.676dup	p.Trp226Leufs*4	1/1	crypto (MeiA – ES)	NM_138804.4	Wyrwoll et al., 2023, 2020
5	RU01691			azoo (MeiA – postmeiotic cells), TESE positive	NM_138804.4	Wyrwoll et al., 2020	
6	MI-0006-P			azoo (MeiA – RS [note: not validated by CREM IHC]), TESE negative	NM_138804.4	Wyrwoll et al., 2020	
7	F1: II-1	c.1435-1G>A	p.?	1/1	severe oligozoospermia	NM_138804	Tu et al., 2020
8		c.1074+2T>C	p.Ala312Lysfs*7	1/1	azoo (M-I arrest – RS [note: not validated by CREM IHC])	NM_001321739.2	Li et al., 2023
9	9-azoo	c.(*142767)_(*153120 )del	p.?	1/1	azoo	NM_001281296.2	Khan et al., 2023

M1AP, ZZS & crossover formation

10	GEMINI-1678	c.676dup	p.Trp226Leufs*4	1/1	severe oligozoospermia	NM_001281296.2	Khan et al., 2023
11	GEMINI-283				NOA	NM_001281296.2	Khan et al., 2023
<b>SHOC1</b>							
1	11-272	c.797del	p.(Leu266Glnfs*6)	1/1	SPC arrest, M-I	NM_173521.4	Krausz et al., 2020
2	M2046	c.[1351del;1347T>A];[945_948del]	p.([Ser451Leufs*23;Cys449*];[Glu315Aspfs*6])	1/1	MA	NM_173521.4	Krausz et al., 2020; this study
3	M2012	c.1085_1086del	p.(Glu362Valfs*25)	1/1	azoo (MA)	NM_173521.4	Krausz et al., 2020; Wyrwoll et al., 2023; this study
4	Family 1	c.1582C>T c.231_232del	p.(Arg528*) p.(Leu78Serfs*10)	1/1	MA (SPC)	NM_173521	Yao et al., 2021
5	Family 2	c.1194del	p.(Leu400Cysfs*8)	1/1	MA	NM_173521	Yao et al., 2021
6	sporadic MA	c.1464del	p.(Asp489Thrfs*14)	1/1	MA	NM_173521	Yao et al., 2021
7	F1:II-2				MA (SPC)	NM_173521	Wang et al., 2022
		c.231_232del	p.(Leu78Serfs*10)	1/1			
8	F2:II-1				MA (SPC)	NM_173521	Wang et al., 2022
9	GEMINI-377	c.1085_1086del	p.(Glu362Valfs*25)	1/1	NA	NM_173521.4	Nagirnaja et al., 2022; this study

**TEX11**

1	Patient 1				mixed testicular atrophy	NM_001003811	Yatsenko et al., 2015
		c.(651+1_652-1)_(888+1_889-1)del		1/-			
2	Patient 3				MeiA	NM_001003811	Yatsenko et al., 2015
3	Patient 4	c.1837+1G>C	p.?	1/-	MeiA (RS [note: not validated by CREM IHC])	NM_001003811	Yatsenko et al., 2015
4	Patient 5	c.792+1G>A	p.?	1/-	MeiA	NM_001003811	Yatsenko et al., 2015
5	WHT3759	c.1259_1260insTT	p.(Trp421Cysfs*25)	1/-	MA (pachytene)	NM_031276	Yang et al., 2015
6	WHT2445	c.1793-1G>A	p.?	1/-	azoo	NM_031276	Yang et al., 2015
7	09-297	c.(82+1_83-1)_(651+1_652_1)del		1/-	SPC arrest, M-I	NM_001003811.2	Krausz et al., 2020
8	NOA8	c.2525G>A	p.(Trp842*)	1/-	MA	NM_001003811.1	Chen et al., 2020
9		c.151_154del	p.(Asp51Phefs*8)	1/-	MeiA (RS [note: not validated by CREM IHC])	NM_031276	Yu et al., 2021
10	P5648	c.1796+2T>G	p.?	1/-	MA	NM_001003811	Ji et al., 2021
11	P6825	c.1426-1G>T	p.?	1/-	MA	NM_001003811	Ji et al., 2021

M1AP, ZZS & crossover formation

12	P8122	c.1253dup	p.(Asn418Lysfs*10)	1/-	MA	NM_001003811	Ji et al., 2021
13	P8251	c.298del	p.(Val100Leufs*6)	1/-	NOA	NM_001003811	Ji et al., 2021
14	P5048	c.1051G>T	p.(Glu351*)	1/-	MA	NM_001003811	Ji et al., 2021
15	P9225	c.857del	p.(Lys286Argfs*6)	1/-	NOA	NM_001003811	Ji et al., 2021
16	A2799	c.2240C>A	p.(Ser747*)	1/-	MeiA	NM_031276	An et al., 2021
17	A2153	c.1246C>T	p.(Gln416*)	1/-	NOA	NM_031276	An et al., 2021
18	NOA49	c.559_560del	p.(Met187Valfs*6)	1/-	MA	NM_031276	Tang et al., 2022
19	P3	c.313C>T	p.(Arg105*)	1/-	MA, TESE negative	NM_031276	Song et al., 2023
20	M1390	c.(159+1_160-1)_(692+1_693-1)del		1/-	MeiA	NM_001003811.2	Wyrwoll et al., 2023

abbreviations: c = coding DNA reference sequence, p = protein reference sequence, azoo = azoospermia, crypto = cryptozoospermia, MeiA, meiotic arrest, M-I = metaphase I arrest, MA = maturation arrest, RS = round spermatid, SPC = spermatocyte, NA = no information, NOA = non-obstructive azoospermia, TESE = testicular sperm extraction

150 **Appendix Table S3. Antibody information.**

Target	Species	Dilution, individual protocol requirements	Source
<b>primary antibodies</b>			
CREM	rabbit, polyclonal	IHC: 1:2000 pH 6	Sigma Aldrich, #HPA001818
H3S10p	rabbit, polyclonal	IHC: 1:2500, pH 9	GeneTex, #GTX128116
$\gamma$ H2AX	mouse, monoclonal	IHC: 1:30 in TBS + 0.01% Tween, pH 9 IF (meiotic spreads): 1:1000	Merck, #05-636
TEX11	rabbit, polyclonal	IF (meiotic spreads): 1:25 WB: 1:500	Sigma, #HPA002950
SYCP3	rabbit, polyclonal	IF (meiotic spreads): 1:500	R&D Systems, #AF3750
SYCP1	rabbit, polyclonal	IF (meiotic spreads): 1:50	Novus Biological, #NB300-228
ACA	human, polyclonal	IF (meiotic spreads): 1:150	Biozol, #15-234
MLH1	human, monoclonal	IF (meiotic spreads): 1:25	BD Bioscience, #550838
DYK	mouse, monoclonal	WB: 1:1500	Merck, #F3165
HA	rat, monoclonal	WB: 1:1500	Sigma Aldrich, #11867423
Isotype control	mouse	adapted to primary antibody	Merck, #I5381
Isotype control	rabbit	adapted to primary antibody	Merck, #I5006
Isotype control	goat	adapted to primary antibody	Merck, #I5256
<b>secondary antibodies</b>			
anti-rabbit biotin	goat, polyclonal	IHC: 1:100	abcam, #ab6012
anti-mouse biotin	goat, polyclonal	IHC: 1:100	abcam, #ab5886
anti-mouse HRP	donkey, recombinant	WB: 1:1000	Santa Cruz, #sc-516102
anti-rat HRP	goat, polyclonal	WB: 1:1000	Sigma-Aldrich, #A9037

anti-human DyLight 405	donkey	IF (meiotic spreads): 1:400	Jackson Immuno, #709-475-149
anti-goat Alexa Fluor 488	donkey	IF (meiotic spreads): 1:500	Thermo Fisher, #A11055
anti-mouse Alexa Fluor 568	donkey	IF (meiotic spreads): 1:500	Thermo Fisher, #A10037
anti-mouse Alexa Fluor Plus 647	donkey	IF(meiotic spreads): 1:500	Thermo Fisher, #A32787
anti-rabbit Alexa Fluor 568	donkey	IF (meiotic spreads): 1:500	Thermo Fisher, #A10042
anti-rabbit Alexa Fluor Plus 647	donkey	IF (meiotic spreads): 1:500	Thermo Fisher, #A32795
<b>others</b>			
Streptavidin HRP		IHC: 1:500	Sigma-Aldrich, #S5512
Fab anti-human	goat	IF (meiotic spreads): 50 µg / mL	Jackson Immuno, #109-007-003

152 **Appendix Table S4. Primer information.**

Target	Primer sequences (5' – 3')
<b>Sanger sequencing</b>	
M1AP c.676dup	F: TGGGTCTGAAAATGTTGCTGA R: GATTGCTAGAGCCCAGGCAT
M1AP c.1073_1074+10del	F: ACAGAATATATATCTAGGGCTTGACAC R: GAGTCTGCTTCAACTCTTCCCA
SHOC1 c.1085_1086del	F: GCAGAGCCAGGGCCTATATG R: AATTCAAGAGCCCCACAGCC
SHOC1 c.1351del + c.1347T>A	F: TGGTCCTGTGCAGTCAAGTT R: ACACTCGTTTAGGTGTGGAAGT
SHOC1 c.945_948del	F: CCCACATTTCTACTCGTTGTACC R: CTTGAATCTGGGGCGGAGG
SHOC1 c.1939+2T>C	F: TGTCAATTAGGAGCTTCACTGAG R: TGCAGATAGCCAGTGCCAA
TEX11 c.450C>T	F: TGTGGAGTTCAAAGTAGAACACAGAAC R: TCCAATCAGCATTAGTAACATCACC
TEX11 c.1425G>A	F: TGTTGACCAAGACTGATAATAAAATGC R: CAGTGTGCAAATCAAGAAAATGTC
TEX11 c.22del	F: CGTTGCCAGGCAGACTTATG R: GGGATTACCACGCCCAAC
TEX11 c.1096dup	F: CACTCTCCAGCACTGGATGTTAATAC R: ATTGCCAAGGTTGGTCTCAAG
TEX11 c.792+1G>A	F: GCCAAATGGAAAAAGGCATC R: ACCCAAACATTGTTCAAAGCAC
TEX11 c.1837+1G>C	F: ATGAGGGCACTGGGAATGAG R: TCTCTGCTTGTGAATGAAGAAACC
TEX11 c.1245G>A	F: GGAGAATCAGGCAGCAGTACC R: CAGCGATGACATTTCCCTACAC
TEX11 c.731G>A	F: TTCTCCAACCTGAATGTTTTGC R: AAGGAAGGAAGAACACATTTTTCTATG

SPO16 Exon 4	F: ACTACCCAGTATCTTCATGTGGA R: CCACAGAGGATTTGAGATGGCT
pcDNA3.1	F: GTAACAACCTCCGCCCCATTG R: AGGAAAGGACAGTGGGAGTG
SHOC1 WT (cDNA)	F: GCCAAGAATTCAAGAGCCCC R: CCTGCTTGTTTCCACCACTC
SHOC1 WT c.287 (cDNA)	F: GTAGTAGAAAACACCTACC
SHOC1 WT c.803 (cDNA)	F: CTCTATTCCTAACATGCC
SHOC1 WT c.1324 (cDNA)	F: GCAAAAAGAAGTACCAGATC
SHOC1 WT c.1979 (cDNA)	F: CTCTCTTACATCTTCTGG
SHOC1 WT c.2636 (cDNA)	F: CAGACATACTTCAGCTGC
SHOC1 WT c.3086 (cDNA)	F: GGTTGGATAAATCCTGGC
SHOC1 WT c.3746(cDNA)	F: CTCAGAAGAGAGTGTGAC
SHOC1 WT c.4241 (cDNA)	F: TGTGCTCACAACCTACCAC
TEX11 WT (cDNA)	F: TGGCCTTGCGTTTCCTTAAC R: ACTGGGCCCTTGTTGTTACT
TEX11 WT c.276 (cDNA)	F: AAGCCTCATTTGCCTCAG
TEX11 WT c.809 (cDNA)	F: ATAAGGCTCTCAATGCTG
TEX11 WT c.1404 (cDNA)	F: TGAACGACATGACCCTAG
TEX11 WT c.2021 (cDNA)	F: CAGTTGATCTAGAGCAAG
TEX11 WT c.2700 (cDNA)	F: TAGTCAGCTTGTGGAAGC
SPO16 WT (cDNA)	F: GTTTTGTCTGCTGCCCTCC R: GCATTTACTGTGTTGTGACTGG
SPO16 WT c.355 (cDNA)	F: CTTCCAGTACACAACACAG
<b>ddPCR</b>	
TEX11 WT	F: TGGGTAACTGTGAGGAGAC R: CAATTCTCCCCTCTCCCTAC
TEX11 (probe)	FAM-ACGCTGAGTGAAACAAGCCAGTC-BHQ1



---

Reference WT (ZIC1)	F: CTCTGGCTACGAATCCTCC R: CAATTCTCCCCTCTCCCTAC
---------------------	---

---

Reference (ZIC1, probe)	HEX- CGCCTCCCACCATCGTGTCT
-------------------------	---------------------------

---

**Minigene assay**

M1AP in Ex7 F-seq	F: CACCTCTGCTTCAACTCTTCCCAGT R: TACACCTGGAATGCTCTGCC
-------------------	---

---

M1AP aus Ex7 R-seq	F: TGTA AACGACGGCCAG R: AGCAGGCTGTGACACAAAGCATG
--------------------	--

---

SHOC1 c1339+2 MiniGene	F: CACCTTCAGATAGAAGTTCGGATCTCC R: TGGTTTGGCTGGGTATCACA
------------------------	---

---


SHOC1 Ex13	F: ACCCTCCCTACTGCTAATTGG
------------	--------------------------

---

rat insulin	F: CCTGCTCATCCTCTGGGAGC R: AGCAGGCTGTGACACAAAGCATG
-------------	---

---


## 154 Appendix Figures



155  
156  
157  
158  
159  
160  
161  
162  
163

**Appendix Figure S1. M1AP splice site variant identified in M3609.** A. Amplified minigene cDNA encompassing – c.1073\_1074+10del or respective wildtype (control/WT) sequence. B. Schematic illustration of variant effect on genomic, transcriptomic, and protein level combined with sequencing results for each minigene product reveals aberrant splicing. In the WT minigene construct, M1AP exon 7 (Ex7) is encompassed by two known exons of rat *Insulin 2*, exon 3 and exon 4 (rat *Ins2* Ex3/Ex4). In M3609, the variant led to two splicing products: one (MUT1) showed the recognition of a cryptic splice site leading to a frameshift and premature stop codon in M1AP exon 8. The second (MUT2) resulted in skipping of exon 7 and a premature stop codon in exon 8. C. Both splicing products lead to the loss of amino acids, presumably effecting M1AP's function and interaction.

164




165

166 **Appendix Figure S2. SHOC1 splice site variant identified in M3260 with predominant meiotic arrest and rare**  
 167 **round spermatids.** A. *SHOC1* (NM\_173521.5) has 26 exons and its corresponding protein comprises 1444 amino  
 168 acids. Amplified minigene cDNA encompassing – c.1939+2T>C (M3260) or respective wildtype (control/WT)  
 169 sequence. B. Schematic illustration of variant effect on genomic, transcriptomic, and protein level combined with  
 170 sequencing results for each minigene product reveals aberrant splicing. In the WT minigene construct, *SHOC1*  
 171 exon 13 (Ex13) is encompassed by two known exons of rat *Insulin 2*, exon 3 and exon 4 (rat *Ins2* Ex3/Ex4). In  
 172 M3260, the variant resulted in in-frame skipping of exon 13 and a predictive loss of 59 amino acids representing  
 173 4% of the total protein. C. This affects the distant helicase hits region but not the highly conserved ‘SHOC1  
 174 homology region’ (amino acids 937-1105, NP\_775792; Macaisne et al., 2008). This region contains an XPF  
 175 endonuclease-like central and a helix-hairpin-helix (HhH<sup>2</sup>) domain and is important for the XPF-ERCC1-like  
 176 complex formation between SHOC1 and SPO16 (De Muyt et al., 2018; Zhang et al., 2019). Yeast studies  
 177 highlighted that the N-terminal part of Zip2 is linked to the chromosome axis and the other ZMM components through  
 178 Zip4 interaction, while the XPF domain interacts exclusively with Spo16 (De Muyt et al., 2018). Given that M3260  
 179 expresses all exons of *SHOC1* except for exon 13, the interaction with SPO16 and in parts with the ZMM proteins,  
 180 such as TEX11, remains intact. However, a changed protein conformation due to the loss of exon 13 could influence  
 181 some of these interactions and explain the observed phenotype of predominant meiotic arrest with rare round  
 182 spermatids (D) that were positive for CREM-staining (E). (F) H3S10 staining showed only aberrant metaphase I-

183 like spermatocytes (M-I\*). (G) TUNEL staining showed an increased number of apoptotic spermatocytes similar to  
184 patients with complete LoF variants in *M1AP*, *SHOC1*, *TEX11*, or *SPO16*. (H) In  $\gamma$ H2AX staining, single tubules  
185 contained pachytene-like cells (P) with a clearly distinguishable XY body were observed, which is in line with the  
186 presence of round spermatids. In addition, also aberrant pachytene-like cells were present. (I) The specific type of  
187 arrest of M3260 is described as a metaphase I arrest (MM-I) with rare round spermatids (RS).


188



189

190 **Appendix Figure S3. SPO16 loss-of-function variant identified in M3863.** A. Sanger sequencing of M3863  
 191 revealed the frameshift variant c.266del leading to premature stop codon (p.Leu89Trpfs\*15). B. Such a truncated  
 192 protein would lack the highly conserved helix-hairpin-helix (HhH<sup>2</sup>) domain which is important for the XPF-ERCC1-  
 193 like complex formation between SHOC1 and SPO16 (De Muyt et al., 2018; Zhang et al., 2019). C. Conversation  
 194 analysis of the SPO16 variant. D. The premature stop codon would truncate 42.5% of the complete protein.

195




196

197 **Appendix Figure S4. Overview of clinical data of men with loss-of-function variants in *M1AP*, *SHOC1*, *TEX11***  
 198 **or *SPO16*.** Exome data of men with variants in *M1AP* (N=10), *SHOC1* (N=4), *TEX11* (N=9), and *SPO16* (N=1) was  
 199 queried and depicted data shows the median values with the respective 95% confidence intervals. A. Bi-testicular  
 200 volume (mL). B. Serum FSH (U/L). C. Serum LH (U/L). D. Serum testosterone (nmol/L). Blue areas represent  
 201 respective reference values (FSH = 1-7 IU/L, LH = 2-10 IU/L, T ≥ 12 nmol/L, bi-testicular volume ≥ 24 mL per testis.)


202

203



204


205 **Appendix Figure S5. PAS (N=7) or H&E (N=3) staining of men with LoF variants in *M1AP*.** All men carrying  
 206 variants in *M1AP* underwent attempts for testicular sperm retrieval (TESE, N=10). Overview staining revealed  
 207 testicular architecture and germ cell types were quantified for each tubule. SPC = spermatocyte, RS = round  
 208 spermatid, ES = elongated spermatid. The scale bar represents 100  $\mu$ m and 10  $\mu$ m, respectively.



209


210 **Appendix Figure S6. PAS (N=6) or H&E (N=3) staining of men with LoF variants in *SHOC1*, *TEX11* or *SPO16*.**  
 211 Ten of 14 men carrying variants in *SHOC1*, *TEX11* or *SPO16* underwent testicular surgery for TESE attempt.  
 212 Overview staining revealed the testicular architecture and germ cell types were quantified for each tubule. SPC =  
 213 spermatocyte. The scale bar represents 100  $\mu$ m and 10  $\mu$ m, respectively.





215 **Appendix Figure S7. CREM staining in men with loss-of-function variants in *M1AP*, *SHOC1*, *TEX11* or**  
216 ***SPO16*.** Testicular tissue was stained for CREM to analyse development of haploid round spermatids (RS). Positive  
217 cells are indicated in the magnification. The scale bar represents 100  $\mu\text{m}$  and 10  $\mu\text{m}$ , respectively.


218



219


220 **Appendix Figure S8.  $\gamma$ H2AX localisation showed meiosis prophase I progression in men with loss-of-**  
 221 **function variants in *M1AP*.** Testicular tissue was stained for the DSB marker  $\gamma$ H2AX. Meiotic prophase I substages  
 222 (L = leptotene-, Z = zygotene-, P = pachytene-, D = diplotene-like) and metaphase I (M-I)-like were identified and  
 223 depicted in the detail view for each man. Besides, aberrant,  $\gamma$ H2AX-positive metaphase-like cells are shown (black  
 224 arrow head). Pachytene-like cells are indicated in the magnification. The scale bar represents 100  $\mu$ m and 10  $\mu$ m,  
 225 respectively.

226



227


228 **Appendix Figure S9.  $\gamma$ H2AX localisation showed impaired meiosis prophase I progression in men with loss-**  
 229 **of-function variants in *SHOC1*, *TEX11* or *SPO16*.** Testicular tissue was stained for the DSB marker  $\gamma$ H2AX. In  
 230 M2046 and G-377, the majority of cells reached only a zygotene-like stage. Contrary to the other men with LoF  
 231 variants in *TEX11*, one man with a frameshift variant in *TEX11* (M3409) had few pachytene-like cells in two of 86  
 232 counted seminiferous tubules. These cells had an enlarged XY body-like structure with accumulated  $\gamma$ H2AX. Meiotic  
 233 prophase I substages (L = leptotene-, Z = zygotene-like) and arrested zygotene- (Z\*), pachytene- (P\*) and  
 234 metaphase I-like cells (M-I\*) were identified and depicted in a detail view. The scale bar represents 100  $\mu$ m and  
 235 10  $\mu$ m, respectively.



236  
237  
238

**Appendix Figure S10. Metaphase I cells were determined by H3S10p localisation in men with loss-of-function variants in *M1AP*, *SHOC1*, *TEX11* or *SPO16*. Testicular tissue was stained for H3S10p to detect**

239 diakinesis / aberrant metaphase-I-like (M-I\*) or normal metaphase I-like (M-I) cells. Localisation of positive cells  
240 was taken into account to distinguish between mitotic (spermatogonia = mitosis) and meiotic (spermatocyte) M-I  
241 cells (indicated in magnification). The scale bar represents 100  $\mu\text{m}$  and 10  $\mu\text{m}$ , respectively.  
242



243


244

245

246

247


**Appendix Figure S11. Quantification of apoptosis in men with loss-of-function variants in *M1AP*, *SHOC1*, *TEX11* or *SPO16* via TUNEL.** Testicular tissue was analysed by TUNEL assay to show apoptotic cells. Positive apoptotic cells, negative diakinesis / metaphase-I-like(M-I) cells, and negative round spermatids (RS) are indicated in the magnification. The scale bar represents 100 µm and 10 µm, respectively.



248

249 **Appendix Figure S12. Human spermatocyte spreads showed the absence of crossover in ZZS cases. A.**  
 250 Meiosis-specific marker for SC assembly (SYCP3 = green), chromosome synapsis (SYCP1 = red), and crossover  
 251 resolution (MLH1 = magenta) were stained on spermatocytes from representative men with loss-of-function (LoF)  
 252 variants in one of the ZZS genes (*SHOC1* = M2046, *TEX11* = M3409, and *SPO16* = M3863). ACA (cyan) was used  
 253 to distinguish homologous chromosomes. LoF in *SHOC1*, *TEX11*, and *SPO16* led to asynapsed chromosomes and  
 254 an early meiotic arrest, where the pachytene stage was never reached and crossover events (MLH1 foci) were  
 255 completely absent on chromosome axes. The scale bar represents 10  $\mu\text{m}$ .






256

257 **Appendix Figure S13. Human spermatocyte spreads showed meiotic delay in ZYS cases.** Meiosis-specific  
 258 marker for synaptonemal complex assembly (SYCP3 = green), DNA double-strand breaks ( $\gamma$ H2AX = red), and ZYS  
 259 recruitment (TEX11 = magenta) were stained on spermatocytes from representative men with loss-of-function (LoF)  
 260 variants in *M1AP* or one of the ZYS genes (*M1AP* = M864, *SHOC1* = M2046, *TEX11* = M3409, and *SPO16* =  
 261 M3863). ACA (cyan) was used to distinguish homologous chromosomes. LoF in *SHOC1*, *TEX11*, and *SPO16* was  
 262 associated with an early meiosis I defect including incomplete DSB repair and disturbed assembly of early  
 263 recombination intermediates (TEX11 foci), whereas the man with a LoF variant in *M1AP* had qualitatively normal  
 264 meiosis I progression. However, the recruitment of TEX11 to the chromosomal axis was reduced compared to a  
 265 control with qualitatively and quantitatively normal spermatogenesis. The scale bar represents 10  $\mu$ m.


266



267

268 **Appendix Figure S14. Euploidy analysis of M2746, his child, and the child's mother.** Genome sequencing  
269 data was queried and read counts were normalised by dividing the median read count of each chromosome by the  
270 median read count of all autosomes. Normalised ( $\log^2$ ) read counts of autosomes (0.97 to 1.06) and of gonosomes  
271 (0.49 to 0.51) gave no evidences for chromosome aneuploidies.


272



273

274 **Appendix Figure S15. Staining of testicular tissue from a representative human control.** A. Isotype control  
 275 (IgG). B. Omission of first antibody control (OC). C. CREM staining. D. TUNEL assay. E.  $\gamma$ H2AX staining. F. H3S10p  
 276 staining. Positive cells are indicated in the magnification. The scale bar represents 100  $\mu$ m and 10  $\mu$ m.


277



278

279 **Appendix Figure S16. Digital droplet PCR confirmed the deletion of *TEX11* exons 1-11 in M2820.** A./B. The  
 280 1D-plot showed a clear division of positive droplets (blue and green bands/peaks) and negative droplets (grey  
 281 bands/peaks), which is an important quality parameter. Depicted are the *TEX11* (A) and a reference (ZIC1, B)  
 282 measurements. C. The 2D-plot with four distinct droplet groups (6-FAM-positive droplets (blue), HEX-positive  
 283 droplets (green), double positive droplets (orange) and negative droplets (grey)) confirmed the probe specificity. D.  
 284 Calculated copy numbers showed the deletion of the respective region of *TEX11* in M2820. The H<sub>2</sub>O control did not  
 285 show any fluorescent droplets, as expected. The female control shows a copy number of two and the male control  
 286 shows a copy number of one, as *TEX11* is a X-chromosomal gene. M2820's father carries one copy, as expected.  
 287 However, his mother only shows one copy and therefore is a heterozygous carrier of the deletion.

288



289

290 **Appendix Figure S17. Digital droplet PCR confirms the deletion of *TEX11* exons 10-11 in M3152.** A./B.  
 291 Positive and negative droplets were clearly distinguishable in the *TEX11* and reference measurement (ZIC1). C.  
 292 Quality parameter confirmed probe specificity. D. Calculated copy numbers showed the deletion of the respective  
 293 region of *TEX11* in M3152. The H<sub>2</sub>O control did not show any fluorescent droplets and the male control showed a  
 294 copy number of one, as expected for a X-chromosomal gene. M3152's father carried one copy, as expected.  
 295 However, his mother only showed one copy and therefore is a heterozygous carrier of the deletion.

296

297

298 **Appendix Reference**

- 299 An, M., Liu, Y., Zhang, M., Hu, K., Jin, Y., Xu, S., Wang, H., Lu, M., 2021. Targeted next-generation  
300 sequencing panel screening of 668 Chinese patients with non-obstructive azoospermia. *J. Assist.*  
301 *Reprod. Genet.* 38, 1997–2005.
- 302 Chen, S., Wang, G., Zheng, X., Ge, S., Dai, Y., Ping, P., Chen, X., Liu, G., Zhang, J., Yang, Y., Zhang,  
303 X., Zhong, A., Zhu, Y., Chu, Q., Huang, Y., Zhang, Y., Shen, C., Yuan, Y., Yuan, Q., Pei, X., Cheng,  
304 C.Y., Sun, F., 2020. Whole-exome sequencing of a large Chinese azoospermia and severe  
305 oligospermia cohort identifies novel infertility causative variants and genes. *Hum. Mol. Genet.* 29,  
306 2451–2459.
- 307 De Muyt, A., Pyatnitskaya, A., Andréani, J., Ranjha, L., Ramus, C., Laureau, R., Fernandez-Vega, A.,  
308 Holoch, D., Girard, E., Govin, J., Margueron, R., Couté, Y., Cejka, P., Guérois, R., Borde, V., 2018.  
309 A meiotic XPF–ERCC1-like complex recognizes joint molecule recombination intermediates to  
310 promote crossover formation. *Genes Dev.* 32, 283–296.
- 311 Dicke, A.K., Albrethsen, J., Hoare, B.L., Wyrwoll, M.J., Busch, A.S., Fietz, D., Pilatz, A., Bühlmann, C.,  
312 Juul, A., Kliesch, S., Gromoll, J., Bathgate, R.A.D., Tüttelmann, F., Stallmeyer, B., 2023. Bi-allelic  
313 variants in INSL3 and RXFP2 cause bilateral cryptorchidism and male infertility. *Hum. Reprod.* 38,  
314 1412–1423.
- 315 Ji, Z., Yao, C., Yang, C., Huang, C., Zhao, L., Han, X., Zhu, Z., Zhi, E., Liu, N., Zhou, Z., Li, Z., 2021.  
316 Novel Hemizygous Mutations of TEX11 Cause Meiotic Arrest and Non-obstructive Azoospermia  
317 in Chinese Han Population. *Front. Genet.* 12, 1–10.
- 318 Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tunyasuvunakool, K.,  
319 Bates, R., Žídek, A., Potapenko, A., Bridgland, A., Meyer, C., Kohl, S.A.A., Ballard, A.J., Cowie,  
320 A., Romera-Paredes, B., Nikolov, S., Jain, R., Adler, J., Back, T., Petersen, S., Reiman, D., Clancy,  
321 E., Zielinski, M., Steinegger, M., Pacholska, M., Berghammer, T., Bodenstein, S., Silver, D.,  
322 Vinyals, O., Senior, A.W., Kavukcuoglu, K., Kohli, P., Hassabis, D., 2021. Highly accurate protein  
323 structure prediction with AlphaFold. *Nature* 596, 583–589.
- 324 Karczewski, K.J., Francioli, L.C., Tiao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L., Laricchia,  
325 K.M., Ganna, A., Birnbaum, D.P., Gauthier, L.D., Brand, H., Solomonson, M., Watts, N.A., Rhodes,  
326 D., Singer-Berk, M., England, E.M., Seaby, E.G., Kosmicki, J.A., Walters, R.K., Tashman, K.,  
327 Farjoun, Y., Banks, E., Poterba, T., Wang, A., Seed, C., Whiffin, N., Chong, J.X., Samocha, K.E.,  
328 Pierce-Hoffman, E., Zappala, Z., O'Donnell-Luria, A.H., Minikel, E.V., Weisburd, B., Lek, M., Ware,  
329 J.S., Vittal, C., Armean, I.M., Bergelson, L., Cibulskis, K., Connolly, K.M., Covarrubias, M.,  
330 Donnelly, S., Ferriera, S., Gabriel, S., Gentry, J., Gupta, N., Jeandet, T., Kaplan, D., Llanwarne,  
331 C., Munshi, R., Novod, S., Petrillo, N., Roazen, D., Ruano-Rubio, V., Saltzman, A., Schleicher, M.,  
332 Soto, J., Tibbetts, K., Tolonen, C., Wade, G., Talkowski, M.E., Aguilar Salinas, C.A., Ahmad, T.,  
333 Albert, C.M., Ardissino, D., Atzmon, G., Barnard, J., Beaucher, L., Benjamin, E.J., Boehnke, M.,  
334 Bonycastle, L.L., Bottinger, E.P., Bowden, D.W., Bown, M.J., Chambers, J.C., Chan, J.C.,  
335 Chasman, D., Cho, J., Chung, M.K., Cohen, B., Correa, A., Dabelea, D., Daly, M.J., Darbar, D.,  
336 Duggirala, R., Dupuis, J., Ellinor, P.T., Elosua, R., Erdmann, J., Esko, T., Färkkilä, M., Florez, J.,  
337 Franke, A., Getz, G., Glaser, B., Glatt, S.J., Goldstein, D., Gonzalez, C., Groop, L., Haiman, C.,  
338 Hanis, C., Harms, M., Hiltunen, M., Holi, M.M., Hultman, C.M., Kallela, M., Kaprio, J., Kathiresan,  
339 S., Kim, B.J., Kim, Y.J., Kirov, G., Kooner, J., Koskinen, S., Krumholz, H.M., Kugathasan, S., Kwak,  
340 S.H., Laakso, M., Lehtimäki, T., Loos, R.J.F., Lubitz, S.A., Ma, R.C.W., MacArthur, D.G., Marrugat,  
341 J., Mattila, K.M., McCarroll, S., McCarthy, M.I., McGovern, D., McPherson, R., Meigs, J.B.,  
342 Melander, O., Metspalu, A., Neale, B.M., Nilsson, P.M., O'Donovan, M.C., Ongur, D., Orozco, L.,  
343 Owen, M.J., Palmer, C.N.A., Palotie, A., Park, K.S., Pato, C., Pulver, A.E., Rahman, N., Remes,  
344 A.M., Rioux, J.D., Ripatti, S., Roden, D.M., Saleheen, D., Salomaa, V., Samani, N.J., Scharf, J.,  
345 Schunkert, H., Shoemaker, M.B., Sklar, P., Soininen, H., Sokol, H., Spector, T., Sullivan, P.F.,  
346 Suvisaari, J., Tai, E.S., Teo, Y.Y., Tiinamaija, T., Tsuang, M., Turner, D., Tusie-Luna, T.,  
347 Vartiainen, E., Watkins, H., Weersma, R.K., Wessman, M., Wilson, J.G., Xavier, R.J., 2020. The  
348 mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 581, 434–443.
- 349 Khan, M.R., Akbari, A., Nicholas, T.J., Castillo-Madeen, H., Ajmal, M., Haq, T.U., Laan, M., Quinlan,  
350 A.R., Ahuja, J.S., Shah, A.A., Conrad, D.F., 2023. Genome sequencing of Pakistani families with

- 351 male infertility identifies deleterious genotypes in SPAG6, CCDC9, TKTL1, TUBA3C, and M1AP.  
352 *Andrology* 1–12.
- 353 Kishore, S., Khanna, A., Stamm, S., 2008. Rapid generation of splicing reporters with pSpliceExpress.  
354 *Gene* 427, 104–110.
- 355 Krausz, C., Riera-Escamilla, A., Moreno-Mendoza, D., Holleman, K., Cioppi, F., Algaba, F., Pybus, M.,  
356 Friedrich, C., Wyrwoll, M.J., Casamonti, E., Pietroforte, S., Nagirnaja, L., Lopes, A.M., Kliesch, S.,  
357 Pilatz, A., Carrell, D.T., Conrad, D.F., Ars, E., Ruiz-Castañé, E., Aston, K.I., Baarends, W.M.,  
358 Tüttelmann, F., 2020. Genetic dissection of spermatogenic arrest through exome analysis: clinical  
359 implications for the management of azoospermic men. *Genet. Med.* 22, 1956–1966.
- 360 Li, H., Durbin, R., 2010. Fast and accurate long-read alignment with Burrows-Wheeler transform.  
361 *Bioinformatics* 26, 589–595.
- 362 Li, Y., Wu, Y., Khan, I., Zhou, J., Lu, Y., Ye, J., Liu, J., Xie, X., Hu, C., Jiang, H., Fan, S., Zhang, H.,  
363 Zhang, Y., Jiang, X., Xu, B., Ma, H., Shi, Q., 2023. M1AP interacts with the mammalian ZZS  
364 complex and promotes male meiotic recombination. *EMBO Rep.* 24, e55778.
- 365 Macaisne, N., Novatchkova, M., Peirera, L., Vezon, D., Jolivet, S., Froger, N., Chelysheva, L., Grelon,  
366 M., Mercier, R., 2008. SHOC1, an XPF Endonuclease-Related Protein, Is Essential for the  
367 Formation of Class I Meiotic Crossovers. *Curr. Biol.* 18, 1432–1437.
- 368 Martin, M., 2011. Cutadapt removes adapter sequences from high-throughput sequencing reads.  
369 *EMBnet.journal* 17, 10.
- 370 McKenna, A., Hanna, M., Banks, E., Sivachenko, A., Cibulskis, K., Kernytsky, A., Garimella, K.,  
371 Altshuler, D., Gabriel, S., Daly, M., DePristo, M.A., 2010. The genome analysis toolkit: A  
372 MapReduce framework for analyzing next-generation DNA sequencing data. *Genome Res.* 20,  
373 1297–1303.
- 374 McLaren, W., Gil, L., Hunt, S.E., Riat, H.S., Ritchie, G.R.S., Thormann, A., Flicek, P., Cunningham, F.,  
375 2016. The Ensembl Variant Effect Predictor. *Genome Biol.* 17, 122.
- 376 Nagirnaja, L., Lopes, A.M., Charng, W.L., Miller, B., Stakaitis, R., Golubickaite, I., Stendahl, A., Luan,  
377 T., Friedrich, C., Mahyari, E., Fadiel, E., Kasak, L., Vigh-Conrad, K., Oud, M.S., Xavier, M.J.,  
378 Cheers, S.R., James, E.R., Guo, J., Jenkins, T.G., Riera-Escamilla, A., Barros, A., Carvalho, F.,  
379 Fernandes, S., Gonçalves, J., Gurnett, C.A., Jørgensen, N., Jezek, D., Jungheim, E.S., Kliesch,  
380 S., McLachlan, R.I., Omurtag, K.R., Pilatz, A., Sandlow, J.I., Smith, J., Eisenberg, M.L., Hotaling,  
381 J.M., Jarvi, K.A., Punab, M., Rajpert-De Meyts, E., Carrell, D.T., Krausz, C., Laan, M., O'Bryan,  
382 M.K., Schlegel, P.N., Tüttelmann, F., Veltman, J.A., Almstrup, K., Aston, K.I., Conrad, D.F., 2022.  
383 Diverse monogenic subforms of human spermatogenic failure. *Nat. Commun.* 13, 7953.
- 384 Song, J., Sha, Y., Liu, X., Zeng, X., 2023. Novel mutations of TEX11 are associated with non-obstructive  
385 azoospermia 1–8.
- 386 Tang, D., Li, K., Geng, H., Xu, C., Lv, M., Gao, Y., Wang, G., Yu, H., Shao, Z., Shen, Q., Jiang, H.,  
387 Zhang, X., He, X., Cao, Y., 2022. Identification of deleterious variants in patients with male infertility  
388 due to idiopathic non-obstructive azoospermia. *Reprod. Biol. Endocrinol.* 20, 1–11.
- 389 Tu, C., Wang, Y., Nie, H., Meng, L., Wang, W., Li, Y., Li, D., Zhang, H., Lu, G., Lin, G., Tan, Y.Q., Du,  
390 J., 2020. An M1AP homozygous splice-site mutation associated with severe oligozoospermia in a  
391 consanguineous family. *Clin. Genet.* 97, 741–746.
- 392 Varadi, M., Bertoni, D., Magana, P., Paramval, U., Pidruchna, I., Radhakrishnan, M., Tsenkov, M., Nair,  
393 S., Mirdita, M., Yeo, J., Kovalevskiy, O., Tuny, K., Židek, A., Tomlinson, H., Hariharan, D.,  
394 Abrahamson, J., Green, T., Jumper, J., Hassabis, D., Velankar, S., 2024. AlphaF old Prot ein  
395 Structure D atabase in 2024: 1–8.
- 396 Wang, W., Meng, L., He, J., Su, L., Li, Y., Tan, C., Xu, X., Nie, H., Zhang, H., Du, J., Lu, G., Luo, M.,  
397 Lin, G., Tu, C., Tan, Y.Q., 2022. Bi-Allelic variants in SHOC1 cause non-obstructive azoospermia

- 398 with meiosis arrest in humans and mice. *Mol. Hum. Reprod.* 28, 1–13.
- 399 Wyrwoll, M.J., Köckerling, N., Vockel, M., Dicke, A.K., Rotte, N., Pohl, E., Emich, J., Wöste, M., Ruckert,  
400 C., Wabschke, R., Seggewiss, J., Ledig, S., Tewes, A.C., Stratis, Y., Cremers, J.F., Wistuba, J.,  
401 Krallmann, C., Kliesch, S., Röpke, A., Stallmeyer, B., Friedrich, C., Tüttelmann, F., 2023. Genetic  
402 Architecture of Azoospermia—Time to Advance the Standard of Care. *Eur. Urol.* 83, 452–462.
- 403 Wyrwoll, M.J., Temel, Ş.G., Nagirnaja, L., Oud, M.S., Lopes, A.M., van der Heijden, G.W., Heald, J.S.,  
404 Rotte, N., Wistuba, J., Wöste, M., Ledig, S., Krenz, H., Smits, R.M., Carvalho, F., Gonçalves, J.,  
405 Fietz, D., Türkgenç, B., Ergören, M.C., Çetinkaya, M., Başar, M., Kahraman, S., McEleny, K.,  
406 Xavier, M.J., Turner, H., Pilatz, A., Röpke, A., Dugas, M., Kliesch, S., Neuhaus, N., Aston, K.I.,  
407 Conrad, D.F., Veltman, J.A., Friedrich, C., Tüttelmann, F., 2020. Bi-allelic Mutations in M1AP Are  
408 a Frequent Cause of Meiotic Arrest and Severely Impaired Spermatogenesis Leading to Male  
409 Infertility. *Am. J. Hum. Genet.* 107, 342–351.
- 410 Yang, F., Silber, S., Leu, N.A., Oates, R.D., Marszalek, J.D., Skaletsky, H., Brown, L.G., Rozen, S.,  
411 Page, D.C., Wang, P.J., 2015. TEX11 is mutated in infertile men with azoospermia and regulates  
412 genome-wide recombination rates in mouse. *EMBO Mol. Med.* 7, 1198–1210.
- 413 Yao, C., Yang, C., Zhao, L., Li, P., Tian, R., Chen, H., Guo, Y., Huang, Y., Zhi, E., Zhai, J., Sun, H.,  
414 Zhang, J., Hong, Y., Zhang, L., Ji, Z., Zhang, F., Zhou, Z., Li, Z., 2021. Bi-allelic SHOC1 loss-of-  
415 function mutations cause meiotic arrest and non-obstructive azoospermia. *J. Med. Genet.* 58, 679–  
416 686.
- 417 Yatsenko, A.N., Georgiadis, A.P., Röpke, A., Berman, A.J., Jaffe, T., Olszewska, M., Westernströer, B.,  
418 Sanfilippo, J., Kurpisz, M., Rajkovic, A., Yatsenko, S.A., Kliesch, S., Schlatt, S., Tüttelmann, F.,  
419 2015. X-Linked TEX11 Mutations, Meiotic Arrest, and Azoospermia in Infertile Men. *N. Engl. J.*  
420 *Med.* 372, 2097–2107.
- 421 Yu, J., Chen, Z., Zhang, T., Li, Zhiling, Ni, Y., Li, Zhongxiang, 2011. Association of genetic variants in  
422 CFTR gene, IVS8 c.1210-12T[5\_9] and c.1210-35\_1210-12GT[8\_12], with spermatogenetic  
423 failure: Case-control study and meta-analysis. *Mol. Hum. Reprod.* 17, 594–603.
- 424 Yu, X.C., Li, M.J., Cai, F.F., Yang, S.J., Liu, H. Bin, Zhang, H.B., 2021. A new TEX11 mutation causes  
425 azoospermia and testicular meiotic arrest. *Asian J. Androl.* 23, 510–515.
- 426 Zhang, Q., Ji, S.Y., Busayavalasa, K., Yu, C., 2019. SPO16 binds SHOC1 to promote homologous  
427 recombination and crossing-over in meiotic prophase I. *Sci. Adv.* 5, eaau9780.
- 428